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Abstract
In T cells, the transcription factor nuclear factor of activated T cells p (NFATp) is a key regulator of the cytokine genes tumor
necrosis factor (TNF) and interferon-c (IFN-c). Here, we show that NFATp-deficient (NFATp
2/2) mice have a dramatic and
highly significant increase in mortality after Mycobacterium tuberculosis (MTb) infection as compared to mortality of control
animals after MTb infection. Animals deficient in NFATp have significantly impaired levels of TNF and IFN-c transcription and
protein expression in naı ¨ve or total CD4
+ T cells, but display wild-type levels of TNF mRNA or protein from MTb-stimulated
dendritic cells (DC). The rapid mortality and disease severity observed in MTb-infected NFATp
2/2 mice is associated with
dysregulated production of TNF and IFN-c in the lungs, as well as with increased levels of TNF, in their serum. Furthermore,
global blocking of TNF production by injection of a TNF neutralizaing agent at 6 weeks, but not 12 weeks, post-MTb-
infection further decreased the survival rate of both wild-type and NFATp
2/2 mice, indicating an early role for TNF derived
from cells from the monocyte lineage in containment of infection. These results thus demonstrate that NFATp plays a critical
role in immune containment of TB disease in vivo, through the NFATp-dependent expression of TNF and IFN-c in T cells.
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Introduction
Mycobacterium tuberculosis (MTb) is an intracellular bacterium that
causes tuberculosis (TB) infection in humans. Since a healthy
immune system can usually effectively keep the bacilli in check,
,90% of infected humans do not develop active disease in their
lifetime unless they are immunosuppressed by drugs or disease
[1,2,3,4,5,6,7]. A strong multicellular immune response is required
to maintain TB in its latent state after infection [1,4,6,8,9,10]. In
the case of a weakened immune system, latent TB reactivates into
active disease with a significant increase in frequency. HIV
infection is a significant risk factor for the development of active
TB [11,12]. By compromising the immune system, HIV greatly
facilitates the activation of latent TB. TB remains the world’s
deadliest infectious killer next to HIV, claiming approximately 1.5
million human lives annually, and remains the largest cause of
death in HIV co-infected individuals [6,13,14,15,16].
Resistance to TB involves macrophages [2,4], dendritic cells
(DC) [17,18], and T cells [18], and multiple studies in humans and
mice have shown that maintenance of TB latency requires a Th1
T cell immune response and IFN-c, which is a signature cytokine
of this response. Also required are the participation of alveolar
macrophages and T lymphocytes, and the production of cytokines
such as IL-2, IL-12, IL-18, and TNF, as well as chemokines such
as RANTES, MCP-1, MIP-1a, and IL-8, which play an important
role in the migration of different cell populations to the site of
granuloma formation [6,9,10,19]. Humans with genetic deficien-
cies in IFN-c as well as IL-12, which is produced by the
monocyte/macrophage lineage, and/or their receptors are par-
ticularly susceptible to uncontrollable infection by MTb and by
otherwise non-pathogenic strains of atypical mycobacteria and by
Mycobacterium bovis bacillus Calmette-Guerin (BCG)
[5,20,21,22,23]. Consistent with these observations, mice deficient
in the transcription factor T-bet, which is required for IFN-c
production and establishing a general program of Th1 gene
expression [24,25], are particularly susceptible to MTb infection,
which is correlated with relatively decreased IFN-c production as
compared to wild type mice [26].
TNF is produced by a number of cell types, including T cells, B
cells, macrophages, and DCs [27,28]. Regulation of TNF gene
transcription is inducer- and cell type-specific and invovles the
formation of higher-order enhancer complexes, or enhanceo-
somes, at the TNF promoter [27,29,30,31,32,33], as well as distal
regulatory sequences [27,34,35]. TNF plays a critical protective
role in the innate and adaptive response to tuberculosis in humans
and mice [36,37]. For example, active TB was observed to develop
at a high frequency in individuals latently infected with TB who
were treated with a broadly neutralizing antibody against TNF for
Crohn’s disease or rheumatoid arthritis [38]. In mice, TNF has
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growth in vitro [39] and in granuloma formation in vivo [40,41,42].
However, although the role of TNF in the pulmonary inflamma-
tory response to MTb infection has been extensively demonstrated
in murine models, the cellular source of TNF and the relative
contribution of T cell- versus macrophage- or DC-derived TNF in
protection against MTb and in clinical TB infection have not been
defined.
The transcription factor NFATp (also known as NFAT1 and
NFATc2) is a major regulator of T cell-derived cytokine gene
expression [43,44,45,46]. While NFATp plays a critical role in the
transcription of the IFN-c gene [45] and the TNF gene [47,48] in
T cells, it is not required for TNF transcription in the monocyte/
macrophage lineage [33,48]. This was strongly corroborated in vivo
in mice by experiments that showed that NFATp
2/2 mice were
less susceptible to T cell superantigen-induced toxic shock, but
were equally susceptible to lipopolysaccharide (LPS)-induced toxic
shock [48]. Thus, the role of NFATp in the immune response to
MTb infection, particularly in distinct cell types, presents a
question of considerable interest that is tractable in the mouse
model.
Here, we show that NFATp
2/2 mice have a dramatic increase
in mortality after MTb infection relative to wild-type mice (mean
survival of 119 days versus 205 days, p=0.0042), and that they
had an MTb burden in their lungs approximately three orders of
magnitude higher at the symptomatic endpoint relative to the
lungs of wild-type mice at the time of sacrifice (8.6610
8 CFU/lung
versus 8610
5 CFU/lung). We show that in the lungs of MTb-
infected NFATp
2/2 mice, there is a significantly decreased level
of IFN-c mRNA, while there in an initial increase of TNF mRNA
expression that correlates with increased serum levels of TNF
protein. Using in vitro analysis, we show that transcription and
protein expression of TNF or IFN-c from naı ¨ve or total CD4
+ T
cells was significantly impaired in NFATp
2/2 mice, while TNF
transcription and protein expression from DCs stimulated by TB
was identical in NFATp
2/2 and in wild-type mice. Furthemore,
we show that blocking TNF with the pharmacological neutralizing
agent Enbrel has a deleterious impact on survival of wild-type and
NFATp
2/2 mice when administered 6 weeks rather than 12
weeks following MTb infection, with a greater impact upon
NFATp
2/2 mice, indicating an early role for TNF derived from
DC and monocytic cells in susceptibility to TB. Taken together,
these results indicate that through its key role in regulating TNF
and IFN-c, NFATp controls a major checkpoint in T cell cytokine




+/2 mice (a generous gift from L.H. Glimcher,
Harvard School of Public Health, Boston, MA) were bred and
NFATp
2/2 and wild-type (WT) littermates were genotyped by
PCR as previously described [43] until a colony of NFATp
2/2
was established. NFATp
2/2 and WT (BALB/c) mice were harem-
bred and maintained in pathogen-free conditions. Mice were used
for experiments including infection at the age of 6–7 weeks. Their
care was in strict accordance with NIAID and NIMR institutional
guidelines, and all efforts were made to minimize suffering.
Bacteria and infection
MTb (HN878 clinical strain) was grown in 7H9 broth
supplemented as recommended by the manufacturer (Becton
Dickinson, Sparks MD). All animal infection with aerosolized
MTb was performed as previously described [49,50] under BSL3
conditions in the animal facilities at NIAID. Enbrel (Wyeth
Pharmaceuticals) and human isotype control antibody IgG1 (R&D
Systems) were diluted in PBS and given intraperitoneally twice a
week at 0.01 mg/mouse/dose, mimicking the physiological
human dose (0.4 mg/kg) administered for rheumatoid arthritis.
Experiments to determine differences in survival time were
repeated at least twice.
Necropsy and Histology
Mice were sacrificed at described time points and the lungs,
spleen, and any observed lymph nodes were removed aseptically
and divided into portions for bacterial load determination,
leukocyte cell typing and enumeration, RNA preparation, and
histology. Histology tissues were fixed in 10% neutral buffered
Formalin. Tissues were embedded in paraffin and 5–10 mm
sections were cut and stained with H&E and Ziehl-Neelsen acid-
fast stain to localize the acid fast MTb.
FACS analysis of cell surface markers
Age-matched NFATp
2/2 and BALB/c mice (12 each) were
infected with 30.3612 (SD) colony forming units of MTb strain
HN878 per mouse. Lung cells were prepared from naive and
infected mice at 2, 4, and 6 weeks post infection by crushing and
pressing though a cell strainer (Becton Dickinson Labware,
Lincoln Park NJ), lysing the erythrocytes with NH4CL-tris, and
washing twice with DMEM without phenol red and resuspended
to 2610
6 per mL in PBS containing 0.1% bovine serum albumin
and 20% mouse serum. Cells from 2–4 mice were pooled if the
number of viable cells recovered per mouse was less than 1610
6
and microspheres (Caltag laboratories, Burlingame CA) were
added in order to determine the absolute cell number. Pooling was
required for naı ¨ve mice at all time points and for the 2 and 4 week
time points. The cells were stained for 30 min with antibodies
(0.2 mg/10
6 cells) against CD3 (clone 17A2, cy chrome) and
CD11b (M1/70, FITC), and CD45 (clone 30-F11, R-PE), or
CD8a (53-6.7, FITC), CD4 (clone RM4-5, cy chrome), and CD45
(clone 30-F11, R-PE) (BD Biosciences Pharmingen) in PBS
containing 0.1% bovine serum albumin and 20% mouse serum.
The cells were fixed with fixation medium (Caltag Laboratories)
for 12 to 16 hours and analyzed by Fluorescence-activated
cytometry using software provided by with the instrument (BD
Immunocytometry Systems, San Jose, CA). The experiment was
repeated with an additional set of infected mice since more mice
were required per experiment than anticipated and the results
were pooled.
Isolation of murine primary T cells
For T cell purification, spleen cell suspensions from naı ¨ve
(uninfected) mice were first depleted of APCs and CD8
+ T cells
using anti-B220, anti-CD8, and anti-CD11b antibodies. Total
CD4
+ T cells were purified by sorting for CD4
+ and naı ¨ve T cells




using a MoFlo flow cytometer (DakoCytomation). Cells were
stimulated in vitro with anti-CD3/CD28 as described [51,52].
Cytokine measurement by intracellular cytokine staining
(ICS)
Th1 and Th2 CD4
+ T cell subsets were prepared by polarizing
FACS-purified naive CD4
+ T cells from NFATp
2/2 or WT
(BALB/c) mice in the presence of IL-12 and anti-IL4 (Th1
conditions) or IL-4 and anti-IFN-c (Th2 conditions) for six days as
previously described [51,52]. Cells were then stimulated with a
combination of anti-CD3 and anti-CD28 antibodies for 4 h in the
NFATp and TB Infection
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into two pools for double staining with IL-4 and IFN-c or TNF
and IFN-c for analysis by ICS as described elsewhere [34,51].
Generation of BM-DC
Bone marrow (BM) cells were isolated by flushing murine
femurs and tibia with culture medium and differentiated into
dendritic cells (DC) in the presence of GM-CSF (50 ng/ml; a gift
from DNAX Research Institute).
Real-time quantitative PCR
cDNA was synthesized and analyzed by real-time PCR using
specific oligonucleotides as described previously [51,52]. Target
gene mRNA expression was quantified using SYBR green
(Applied Biosystems) and normalized to the ubiquitin mRNA
levels.
Cytokine ELISA
Blood serum from infected mice and supernatants from in vitro
cultures of NFATp
2/2 and WT primary cells were harvested at
indicated time points and TNF and IFN-c secretion was assessed
by ELISA using mouse TNF and mouse IFN-c Kits (R&D
Systems).
Statistics
GraphPad Prism (GraphPad Software, La Jolla California USA,
www.graphpad.com) was used to prepare Kaplan Meier survival
curves, calculate Log-rank test, and median time to morbidity. A
students t-test was used to determine the difference in ELISA
values between treatment and genotyped groups.
Results
NFATp-deficient mice are more susceptible to MTb
infection
We infected 20 WT and 16 NFATp
2/2 mice with the
aerosolized clinical MTb strain HN878 and compared the survival
of the animals. We note that five random mice were sacrificed
after initial infection to demonstrate that the appropriate range
(149 out of a range of 20–200) of MTb colony-forming units (CFU)
had been delivered. Infected mice were then placed in a time-to-
death experiment and were regularly weighed and bled. Any
animals reaching the endpoint established for TB infection
according to the protocol guidelines were sacrificed and at that
time their lung, spleen, and serum were collected for CFU
determination, histological examination, and cytokine analysis.
Since the NFATp
2/2 mice were bred on the relatively TB-
resistant BALB/c background [43,53], BALB/c mice were
employed as the control strain, and the MTb strain HN878,
which has previously been shown to cause accelerated death in
murine TB models [49,54], was used to infect the mice.
As shown in Figure 1A, NFATp
2/2 mice had a dramatically
decreased median TB survival rate (119 days) as compared to WT
mice (205 days, p=0.0042). Consistent with this finding, the CFU
count in the lungs of NFATp
2/2 animals was approximately three
orders of magnitude higher (8.6610
8 CFU/lung) at the symp-
tomatic endpoint as compared to the CFU count in lungs of WT
mice (8610
5 CFU/lung) sacrificed at the same time. Furthermore,
at this morbid stage, the lungs of NFATp
2/2 mice revealed
rampant infection with bacilli outside of granulomas and massive
cellular infiltration of the airways (Figure 1B). By contrast, lungs
from WT animals at the same time post-infection showed
lymphocytic infiltration without exuberant bacterial growth or
evidence of vital tissue damage (Figure 1C), indicating the inability
of the NFATp
2/2 mice to maintain control of the infection.
Dysregulation of IFN-c and TNF mRNA levels in the lungs
of MTb-infected NFATp
2/2 mice. Animals deficient in IFN-c
and TNF or their receptors are highly susceptible to TB [55,56];
however, the cellular source of the TNF that is important in TB
containment has not been identified. Given that transcription of
the Th1 cytokine IFN-c and T cell-derived TNF have previously
been shown to be NFATp-dependent [34,45,48], we next
examined lungs from MTb-infected WT and NFATp-deficient
Figure 1. Increased susceptibility of NFATp
2/2 mice to
aerosolized M. tuberculosis.A .Survival of BALB/c (WT) vs. NFATp
2/2
mice after infection with MTb. 20 WT and 16 NFATp
2/2 mice were
infected with the aerosolized clinical MTb strain HN878 (,149 CFU) and
monitored for survival. B and C. Lung pathology. (B) NFATp
2/2 and (C)
WT mice were infected with MTb, and lungs taken from premortal
NFATp
2/2 mice and from the WT mice sacrificed at the same time were
fixed in 10% neutral buffered Formalin. Fixed tissues were embedded in
paraffin, and 6–10 mm sections were H&E or Ziehl-Neelsen acid-fast
stained as indicated.
doi:10.1371/journal.pone.0041427.g001
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comparison, we also evaluated mRNA levels of the canonical Th2
cytokine gene IL-4 in NFATp
2/2 and wild-type mice, since mice
deficient in IL-4, including mice of the BALB/c background, do
not display decreased survival following MTb infection [56,57,58].
We harvested lungs from two to three WT and two to three
NFATp-deficient mice that were sacrificed between two and ten
weeks after TB infection, then purified total RNA, and performed
real-time PCR using IFN-c-, TNF-, or IL-4-specific primers.
Levels of IFN-c mRNA in the lungs of WT and NFATp
2/2
animals showed the most marked difference at 6 weeks post-TB
infection, at which point the IFN-c mRNA levels were significantly
lower in NFATp
2/2 mice, following relatively reduced levels of
IFN-c mRNA in NFATp
2/2 mice observed at 4 weeks post-TB
infection (Figure 2A). Given the necessity of an intact IFN-c
signaling pathway to control the early stages of murine TB
infection [59], these data are consistent with the enhanced
mortality of the NFATp
2/2 mice. By contrast, TNF mRNA
levels in the lungs of NFATp
2/2 mice markedly peaked 4 weeks
post-TB infection, becoming significantly higher than the corre-
sponding levels in WT mice. By 8 weeks post-infection, however,
WT mice TNF mRNA levels were significantly higher than those
observed in NFATp
2/2 mice (Figure 2B). This is consistent with
enhanced TNF levels secondary to a dramatic inflammatory
response derived from a non-T cell source. In addition, this
dysregulated immune response evident in the lungs of NFATp
2/2
mice is also reflected in the expression of IL-4. Levels of IL-4
mRNA in the lungs were very low up to 8 weeks post-TB infection
regardless of the presence of NFATp (Figure 2C), consistent with
previous studies in WT mice [56,58]. However, NFATp
2/2 mice
showed a marked increase in IL-4 mRNA in the lungs at 10 weeks
post-MTb infection (Figure 2C). This is reminiscent of earlier
studies of splenocytes from this NFATp
2/2 mouse strain in which,
despite an initial defect in early IL-4 transcription, increased
production of IL-4 was observed over the course of the immune
response, coinciding with enhanced Th2 development [43].
In order to rule out that the aberrant cytokine expression was
secondary to perturbed leukocyte recruitment to the lungs in the
NFATp
2/2 mice, we next analysed the cell types present in the
lungs of age-matched uninfected and MTb-infected NFATp
2/2
and WT mice over the course of the first 6 weeks post-infection. As
shown in Figure 3, the timing and number of recruitment of total
leukocytes in the lungs of the NFATp
2/2 and WT mice were
similar (Figure 3A), with only a modest increase the number of
CD11b
+ cells (Figure 3B), indicative of the monocyte lineage,
recruited to the lungs of NFATp





5 cells, respectively, at
6 weeks post-MTb infection). The timing and number of
recruitment of total lymphocytes (Figure 3C), CD3
+ cells
(Figure 3D), and CD4
+ cells (Figure 3E) were also similar in
NFATp
2/2 and WT mice, with a slight increase in the number of
CD8







4, respectively, at 6 weeks post-MTb infection).
Thus, the observed dysregulation of IFN-c or TNF mRNA in the
lungs of NFATp
2/2 mice was not correlated with differential
recruitment of different immune cell populations to the lung.
Taken together, these results demonstrate that production of IFN-
c and TNF are dysregulated in the lungs of NFATp-deficient mice
following MTb infection, particularly within the first six weeks.
Serum TNF levels are increased in NFATp-deficient and
wild-type mice during MTb infection and correlated with
disease severity. AsshowninFigure 4, significantlyhigherlevels
of circulating TNF were detected in the serum of NFATp2/2 mice
at 4 weeks after infection, concordant with the increased TNF
mRNAlevels inNFATp2/2 lungsatthistimepoint,and they were
again elevated at 16 weeks post-infection when the animals began to
show clinical signs of severe disease. By contrast, at 16 weeks after
infection, WT animals still appeared healthy and maintained lower
TNF levels (Figure 4). Notably, near their respective median times of
death (in NFATp2/2 (13 to20 weeks) or WT(30–36 weeks)), when
CFU in the lungs were equivalent in the two groups of mice, there
were no significant differences in TNF levels, which were elevated in
both groups (Figure 4). Thus, increased serum levels of TNF were
correlated with the severity of disease post-infection in both
NFATp2/2 mice and WT mice, and the higher TNF levels in
NFATp2/2 mice were consistent with their more rapid disease
progression and mortality.
Figure 2. Distinct dynamics of cytokine mRNA expression in
the lungs of MTb-infected NFATp
2/2 and WT mice. NFATp
2/2
and WT mice were infected with MTb and total RNA was purified from
the lungs at 2, 4, 6, 8 (8.4), and 10 weeks post-infection. (A) IFN-c,( B)
TNF, and (C) IL-4 mRNA was measured by real-time PCR and values
were normalized to ubiquitin mRNA. Error bars indicate mean of 3
samples 6SD.
doi:10.1371/journal.pone.0041427.g002
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DC but does decrease TNF and IFN-c production by CD4
+ T
cells in vitro. Since TNF produced by T cells is dependent
upon NFATp, the finding that NFATp
2/2 mice were able to
produce high levels of TNF during acute TB infection indicated
that cells other than T cells were able to vigorously produce TNF
in response to TB in an NFATp-independent manner. Given the
central role that DC play in phagocytosis and antigen presentation
during acute TB infection in lungs [60,61] and the high levels of
circulating TNF in these mice, we next investigated whether DC
production of TNF was impacted by NFATp deletion. We derived
BM-DC in vitro from WT and NFATp
2/2 mice, stimulated them
in vitro with a TB sonicate, and analyzed TNF mRNA and protein
levels. Strikingly, the level and kinetics of TNF transcription (up to
6 hours) (Figure 5A) and protein production (up to 24 hours)
(Figure 5B) are not impacted by NFATp deficiency in BM-DC.
By contrast, when we examined TNF gene expression in
primary naı ¨ve and total CD4
+ T cells from WT and NFATp
2/2
mice activated with anti-CD3/CD28 antibodies, TNF mRNA
levels were significantly lower in cells from NFATp
2/2 animals in
response to both first and second cellular stimulations as compared
to their WT counterparts (Figure 5C). Consistent with our
previous findings with bulk CD3
+ T cells [48], these transcrip-
tional differences in TNF were more pronounced at early time
points (within 3 hours) post stimulation (Figure 5C). TNF protein
levels were also lower in naı ¨ve and total CD4
+ T cells at all time
points measured, consistent with the RNA results (Figure 5C).
In the case of IFN-c, undifferentiated populations of T cells,
naı ¨ve and total CD4
+ cells from both WT and NFATp
2/2 mice,
produced very low IFN-c mRNA in response to anti-CD3/CD28
stimulation (Figure 5D) consistent with the fact that the major
source of IFN-c is a differentiated population of T cells (Th1).
When these same T cell populations were stimulated again with
the same antibodies after 6 days of culture in neutral conditions,
IFN-c production was observed in the cells from WT animals
consistent with their spontaneous differentiation into Th1 cells. In
these T cell populations we observed a pronounced difference in
IFN-c gene expression and protein production between WT and
NFATp
2/2 mice at all time points up to 72 and 96 hours, with
the NFATp
2/2 T cells producing significantly less IFN-c mRNA
and protein at all time points (Figure 5D). For comparison, a
previous study showed that at day 14 post-BCG infection,
mediastinal lymph node cells from NFATp
2/2 mice stimulated
with purified protein derivative (PPD) from MTb or with a
combination of anti-CD3 and IL-2 secreted less IFN-c, but not less
IL-5, than WT cells, consistent with a reduced Th1 response [62].
As noted previously, while T cells from NFATp
2/2 mice have
an early defect in IL-4 gene expression following activation, they
display a strong tendency to differentiate into Th2 cells
[43,44,45,63]. This can be ascribed to prolonged maintenance
of IL-4 mRNA expression in NFATp
2/2 T cells; indeed, T cells
from NFATp
2/2IL-4
2/2 mice display wild-type levels of Th2
differentiation [44,45]. We previously demonstrated, using intra-
cellular cytokine staining and FACS analysis, that expression of
TNF protein upon activation by anti-CD3/CD28 of both Th1
and Th2 cells is reduced in NFATp
2/2 mice [34]. Using this
approach, we thus next analyzed Th1 and Th2 cells from wild-
type and NFATp
2/2 mice for expression of TNF, IFN-c, and IL-
4 following activation with anti-CD3/CD28 (Figure 6). IFN-c,a sa
canonical Th1 cytokine, is expressed almost exclusively in Th1
cells, and this expression is markedly reduced in Th1 cells from
NFATp
2/2 mice (Figures 6A and 6B). Similarly, IL-4 is
predominantly expressed in WT Th2 cells, and its expression is
strongly attenuated in NFATp
2/2 Th2 cells (Figure 6A). In
agreement with our previous results [34], TNF is expressed in Th1
and, to a lesser extent, Th2 cells, and the reduction of TNF
expression in NFATp
2/2 cells is much greater in Th2 cells relative
to Th1 cells (Figure 6B). Thus, the decrease in IFN-c and TNF
mRNA and protein expression in activated NFATp
2/2 CD4
+ T
cells is consistent with reduced IFN-c expression in Th1 cells and
Figure 3. Infiltration of leukocytes into the lungs after MTb
infection is similar in NFATp
2/2 and wild-type mice. Age-
matched NFATp
2/2 a n dB A L B / c( W T )m i c ew e r ei n f e c t e dw i t h
aerosolized HN878 MTb strain at ,30 CFU/mouse as described [50].
Lung cell samples from MTb-infected WT (N) and NFATp
2/2 (&) mice
were obtained at 2, 4, and 6 weeks post-infection, and from uninfected
WT (#) and NFATp
2/2 (%) mice at times corresponding to 1, 2, 4, and 6
weeks post-infection, and the number of cells per lung for each
indicated cell population (mean of 3 to 4 samples 6SD) was determined
by FACS for samples at the indicated time points (A–F). The number of
cells recruited to the lung during the course of MTb infection was
determined for total leukocytes (A), CD11b
+ cells, i.e., monocytes (B),
total lymphocytes (C), CD3
+ T cells (D), CD4
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Th2 cells.
Taken together, these experiments correlate impairment of T
cell production of IFN-c and TNF with the increased observed
susceptibility of NFATp
2/2 mice to TB. Moreover, they
demonstrate that production of TNF from the DC compartment
of NFATp
2/2 mice in response to TB stimulation is not impaired
and thus suggest that DC are a major source of NFATp-
independent TNF transcription in this model. These experiments
led us to next investigate whether the timing of TNF production in
both the NFATp
2/2 and WT mice was functionally important in
the immune control of TB infection in these mice and/or the
observed high TNF levels in lung and peripheral blood in the
NFATp
2/2 mice infected with TB were simply a marker of
increased disease and earlier activation of DC or other monocytic
cells where expression of TNF is not dependent upon NFATp.
Early blocking of total TNF signaling post-MTb infection
leads to higher mortality in WT and NFATp
2/2 mice. To
examine whether a further reduction in TNF levels by blocking
TNF production in NFATp
2/2 mice affected the mortality of
these mice, we infected NFATp
2/2 mice and age-matched WT
mice with aerosolized HN878 in the presence or absence of the
Figure 4. Correlation of serum TNF protein levels with MTb disease progression in WT and NFATp
2/2 mice. WT and NFATp
2/2 mice
were infected with the aerosolized clinical MTb strain HN878 at ,100 CFU/mouse as described [50]. Four random mice were bled at four-week
intervals after initial infection and serum levels of TNF were measured by ELISA.
doi:10.1371/journal.pone.0041427.g004
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PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41427Figure 5. Varying NFATp requirement for cytokine expression in different primary cell populations. A and B. TNF expression in BM-
derived dendritic cells is not NFATp-dependent. Primary BM-DC were derived from WT and NFATp
2/2 mice. After 7 days cells were stimulated with
MTb lysates. At indicated time points the cells were lysed to prepare total RNA. (A) TNF mRNA was measured by real-time PCR. (B) TNF protein levels
in the supernatants were measured by ELISA. C and D. TNF and IFN-c expression in murine primary T cells is NFATp-dependent. Purified primary
total CD4
+ and naı ¨ve (CD4
+CD62L
+CD45RB
high) T cells from uninfected WT and NFATp
2/2 mice were stimulated immediately with anti-CD3/CD28
antibody and then left in culture in neutral conditions for another six days and re-stimulated with anti-CD3/CD28 antibodies. Aliquots of cells were
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p75 TNF receptor binding domain attached to the human IgG1
hinge and Fc domains and reversibly binds both human and
murine trimeric TNF [64]. At 6 and 12 weeks after infection, 16
WT and 16 NFATp
2/2 mice were given twice-weekly intraper-
itoneal injections of Enbrel (0.4 mg/kg) and their survival was
monitored. 16 WT and 16 NFATp
2/2 mice served as controls
and were injected at the same times with PBS. In separate
experiments, both a human IgG1 antibody group and a PBS
treated group were used as negative controls for the groups
receiving Enbrel injections; irrelevant IgG treatment yielded
results similar to PBS treatment (data not shown). In addition,
uninfected NFATp
2/2 mice were given intraperitoneal injections
of Enbrel, PBS, or the IgG and no reduction in survival was noted.
At 6 weeks post-infection, prior to treatment with Enbrel, CFU in
the lung and spleen of NFATp
2/2 and WT mice were
approximately equivalent (Figure 7A).
As shown in Figure 7B, anti-TNF treatment administered early
(beginning at 6 weeks post-infection) further significantly decreased
NFATp
2/2 survival by 20 to 28 days (median survival for
NFATp
2/2+PBS mice was 145 vs. 117 for NFATp
2/2+Enbrel
mice; p=0.003). This result is consistent with blockage of TNF
production leading to the increased mortality originating from
monocytic cells such as DC that produce TNF in an NFATp-
independent manner. Blocking TNF with Enbrel administration
decreased the median survival of WT mice (200 vs. 220 days;
p=0.08), but not to the same extent as it did in the NFATp
2/2
deficient mice. The limited effect of Enbrel treatment may be due
to clearance of both Enbrel and the irrelevant antibody by the
mouse immune system. Even when TNF was blocked in the WT
mice, they still had significantly greater survival than the
NFATp
2/2 mice. These results are consistent with other factors
such as IFN-c playing a significant part in the enhanced mortality
observed in NFATp
2/2 mice (Figure 7B).
Strikingly, when anti-TNF treatment was administered late
(beginning at 12 weeks post-infection), it had no significant effect
on disease progression in either WT (median survival 225 days
without vs. 232 days with Enbrel) or NFATp
2/2 (median survival
130.5 days without vs. 132 days with Enbrel) mice (Figure 7C)
indicating that TNF’s role in host defense is most important early
in infection. This result is consistent with the high TNF levels
observed in the mice at the time of disease onset, which is reflective
of the severity of disease. Thus, NFATp is essential for clearance of
MTb even in the presence of high levels of TNF. Furthermore, the
effect of NFATp is broader than its impact upon T cell-derived TNF
production,consistentwith ourobservation of the significantreduction
of IFN-c levels in the lungs and T cells of the NFATp
2/2 mice.
Discussion
Here, we have established a role for one of the NFAT family of
transcription factors, NFATp, in protection against susceptibility
to TB via its key role in regulating IFN-c and T cell-derived TNF.
The NFAT proteins regulate a wide variety of genes involved in
the immune response, organ and tissue development, and T cell
fate [46,65,66,67,68]. Studies employing gene disruption in mice
have demonstrated that NFATp is specifically required for the
expression of T cell-derived TNF [34,43,48] and IFN-c [45]. IFN-
c is a central cytokine in the host Th1 response to MTb infection
in humans as well as mice [6,10,28,55], and patients with genetic
disruptions in IFN-c or the a chain of its receptor, IFN-cR, display
increased susceptibility to mycobacterial infection [5]. Several
studies in mice have shown that TNF is essential to control
infection [37,41,56,69,70,71] and in humans the treatment of
harvested at different time points post-induction as indicated. Purified total RNA was analyzed by real-time PCR with TNF and IFN-c-specific primers,
and cellular supernatants were used to measure TNF and IFN-c protein levels by ELISA.
doi:10.1371/journal.pone.0041427.g005
Figure 6. TNF, IFN-c, and IL-4 production by CD4
+ Th1 and Th2
cells from NFATp-deficient and WT mice. Primary CD4
+ T cells
from NFATp
2/2 or WT mice were polarized into Th1 and Th2
populations for six days and subsequently stimulated with anti-CD3
plus anti-CD28 for 4 h before intracellular cytokine staining (ICS) for IL-4
and IFN-c (A) or TNF and IFN-c (B). NFATp-dependent production of
IFN-c protein by Th1 cells and IL-4 protein by Th2 cells is evident, while
both Th1 and Th2 cells produce TNF protein with a more marked
decrease in TNF expression in Th2 cells from NFATp
2/2 mice.
doi:10.1371/journal.pone.0041427.g006
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activation of latent TB infection [7,38]. The cellular source of the
TNF, however, was not previously known.
Extensive work performed in in vivo mouse models have
demonstrated that anti-MTb immunity in mice is mediated
predominantly by CD4
+ Th1 cells with the aid of CD8
+ T cells
and involves IFN-c signaling [1,3,56,72,73]. Most of these studies
are based on the fact that mice that do not produce IFN-c fail to
inhibit MTb growth and rapidly succumb to the infection.
Mechanistically, several studies have demonstrated that the
impairment of the Th1 cytokine response and IFN-c production
leads to faulty anti-bacterial function in macrophages at sites of
MTb infection [74,75]. An elegant study using mice deficient in
transcription factor T-bet, the master regulatory factor directing
commitment to the Th1 lineage [24,25], demonstrated that their
increased susceptibility to TB was associated with decreased
transcription of the T-bet-dependent IFN-c gene [26]. The
dramatically increased susceptibility to MTb infection that we
observe in NFATp
2/2 mice is consistent with their greatly
impaired expression of IFN-c in the lungs and CD4
+ T cells, from
Th1 cells in particular. Thus, our data from NFATp
2/2 mice
further link the defect of IFN-c gene expression with increased
susceptibility to MTb.
The regulation of IFN-c gene expression by NFATp is part of a
larger network of transcriptional regulation that directs differen-
tiation of naı ¨ve T helper cells into Th1 and Th2 cells [46]. At early
stages of T cell activation, NFATp binds to the promoters of both
the IFN-c and IL-4 genes, but this binding is later restricted to the
IFN-c promoter in Th1 cells and the IL-4 promoter in Th2 cells.
Changes in NFAT binding are accompanied by alterations in
chromatin organization as assayed by DNase hypersensitivity and
histone acetylation at the IFN-c and IL-4 loci [76,77,78]. The
TNF locus also exhibits DNase hypersensitive sites and activation-
dependent histone acetylation in T cells [27,34,79,80,81] as well as
activation-dependent intrachromosomal interactions that involve
NFATp-dependent promoter and enhancer regions [34,82]. In the
experiments presented here, we have shown that naı ¨ve or total
CD4
+ T cells from NFATp
2/2 mice are impaired in their ability
to produce IFN-c and TNF mRNA and protein in response to
MTb infection. We have further delineated the expression of these
cytokines in CD4
+ T helper cell subsets from NFATp
2/2 mice:
Th1-specific expression of IFN-c is impaired and the expression of
TNF in Th1 and Th2 cells is decreased, to a greater extent in Th2
cells.
Unlike IFN-c, which is secreted by Th1 cells, NK cells, and
NKT cells, TNF is expressed in a wide range of cell types,
including T cells, B cells, DCs, macrophages, mast cells, and
fibroblasts, and its cell type- and stimulus-specific regulation
utilizes distinct signal transduction pathways, transcription factors,
and coactivators [27]. We have previously shown that NFATp is a
key activator in TNF gene regulation in T cells stimulated by
calcium flux or via their antigen receptor, but not in monocytes
and macrophages stimulated by LPS or MTb [29,31,32,33,34,83].
In an in vivo toxic shock model, NFATp deficiency renders mice
resistant to superantigen-induced T cell-mediated toxic shock
without affecting their susceptibility to LPS-induced macrophage-
mediated shock [48]. Here we have shown that in NFATp
2/2
mice, while TNF mRNA and protein production is decreased in
activated CD4
+ T cells, BM-DC stimulated by MTb are not
significantly affected in their ability to produce TNF mRNA and
protein. This is consistent with earlier reports that transcriptional
activation of the TNF gene promoter is NFAT-independent in a
murine DC line [84], as is the case in a murine macrophage cell
line [33], in contrast to NFAT-dependent TNF expression in T
cells [29,31,34,83,85,86], B cells [29,87,88,89], and mast cells
[84,90]. The results presented here therefore provide further in vivo
demonstration of the cell type-specific regulation of the TNF gene.
In the context of previous data, these results reinforce the idea that
NFAT-independent TNF expression in cells such as DCs and cells
of the monocyte/macrophage lineage underlie the early peak of
TNF expression we observe in the lungs and serum of NFATp
2/2
mice.
Although T cell-specific expression of both TNF and IFN-c was
significantly impaired in the NFATp
2/2 mice used in our study,
the pattern of dysregulation of TNF expression in the lungs of
NFATp
2/2 mice was distinct from that of IFN-c. While IFN-c
mRNA levels in the lungs of MTb-infected NFATp
2/2 mice were
Figure 7. Time-dependent protective role of TNF during MTb
infection. A. Comparable CFU counts in lungs and spleens from WT
and NFATp
2/2 mice infected with aerosolized MTb. B and C. NFATp
2/2
mice and their BALB/c control mice (WT) were infected with aerosolized
HN878 MTb strain at ,100 CFU/mouse as described [50]. At 6 (B) and
12 (C) weeks post-infection, 16 WT and 16 NFATp
2/2 were given twice-
weekly intraperitoneal injections of Enbrel (0.4 mg/kg) and their
survival was monitored. 16 WT and 16 NFATp
2/2 mice served as
controls and were injected at the same times with PBS.
doi:10.1371/journal.pone.0041427.g007
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expression of TNF mRNA in the lungs in NFATp
2/2 mice was
transiently elevated during the acute phase of TB infection,
reaching a peak 4 weeks post-infection and decreasing 6 weeks
post-infection, while in WT mice the peak occurred approximately
8 weeks post-infection. Serum TNF levels were also higher at 4
weeks post-TB infection in NFATp
2/2 mice relative to WT mice,
and for both WT and NFATp
2/2 mice serum TNF levels rose at
later time points, starting at 16 weeks post-infection, in the
premortal stage of TB. While there is thus a correlation between
increased mortality of MTb-infected NFATp-deficient mice and
increased levels of NFATp-independent TNF in the early stages of
infection, for both NFATp
2/2 and WT mice treatment with the
TNF blocking agent Enbrel starting at 6 weeks post-infection
significantly decreased survival, while injection at 12 weeks post-
infection, when NFATp
2/2 and WT mice had comparable and
relatively low serum levels of TNF, did not affect survival,
indicating that the contribution of TNF against susceptibility to
TB occurs in the early, acute phase of MTb infection.
Furthermore, the increase in mortality upon blocking TNF in
the early phase of TB infection was more pronounced for
NFATp
2/2 mice, consistent with a protective effect of NFATp-
dependent genes, particularly IFN-c, in the host response to
infection.
The T cell-specific defect in production of both IFN-c and TNF
in NFATp
2/2 mice, and the lack of a robust Th1 immune
response to MTb infection, underlie the increased susceptibility of
NFATp
2/2 mice to TB infection. Consistent with this idea,
bacterial proliferation in the lungs of NFATp
2/2 mice was
markedly higher than in WT mice, and this increased bacterial
burden, consistent with their relatively sicker state, could be
expected to activate the monocytic compartment to produce high
levels of TNF mRNA in lungs and protein in serum. This would
likely include alveolar macrophages, which serve as the first line of
defense from MTb pulmonary invasion [2]. While the cellular
source and associated signal transduction pathways underlying the
increase in TNF in the lungs of NFATp
2/2 mice in the early
phase of MTb infection remain to be elucidated, we have
demonstrated that NFATp
2/2 mice display a defect in IFN-c
expression in Th1 cells as well as in the lungs, while TNF
expression is reduced in Th1 and, to a relatively greater extent,
Th2 cells, but is not affected in DCs.
More broadly, this study has pinpointed a specific transcription
factor involved in susceptibility to TB infection and has
highlighted the important role of T cell-derived TNF and IFN-
c. The results presented here thus provide a framework for
dissecting the cell type-specific role of NFATp and its upstream
signal transduction pathways in the regulation of inflammatory
response genes in general, and TNF in particular, involved in
MTb infection.
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